Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on July 17, 2024. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The Board of Directors increased the number of directors from eight to nine. Manuel Hidalgo Medina, M.D., Ph.D., was appointed as a Class II director, effective July 17, 2024. Dr. Hidalgo was also appointed to the nominating and corporate governance committee.
Management Commentary and Compensation
Dr. Hidalgo brings over 20 years of experience in translational and clinical research in anticancer drug development, with a focus on gastrointestinal and pancreatic cancers. He currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and is a board member of Bristol-Myers Squibb Company.
Compensation for Dr. Hidalgo includes:
- A stock option award valued at $362,500.
- A restricted stock unit award valued at $362,500.
- Total initial award value of $725,000.
- Vesting schedule: 25% on the first anniversary of appointment, with the remaining 75% vesting monthly over the subsequent three years.
The Company also entered into a standard indemnification agreement with Dr. Hidalgo.
Investor Verification Checklist
- Verify the total number of directors on the Board is now nine.
- Confirm the vesting schedule for the $725,000 in initial equity awards granted to Dr. Hidalgo.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Note that no financial results or guidance were disclosed in this specific filing.